17 Matching Annotations
  1. Last 7 days
    1. Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia

      [Paper-level Aggregated] PMCID: PMC4477877

      Evidence Type(s): Predisposing, Functional, Oncogenic

      Justification: Predisposing: The identification of germline ETV6 mutations, such as L349P and N385fs, in kindreds affected by thrombocytopenia and acute lymphoblastic leukemia (ALL) suggests a hereditary predisposition to leukemia. Functional: The study demonstrates that the ETV6 mutations impair nuclear localization and transcriptional regulation of ETV6 target genes, indicating a functional impact on the protein's ability to perform its role as a transcription factor. Oncogenic: The presence of ETV6 mutations in individuals with ALL and their association with leukemic phenotypes suggest that these mutations may contribute to oncogenesis in the context of leukemia.

      Gene→Variant (gene-first): ETV6(2120):11905459G>A ETV6(2120):12022436 G>A ETV6(2120):R181H ETV6(2120):V37M ETV6(2120):rs150089916 IKZF1(10320):415 T>C ETV6(2120):L349P ETV6(2120):c. T1046C ETV6(2120):proline for leucine at codon 349 ETV6(2120):N385fs ETV6(2120):P214L ETV6(2120):R369Q ETV6(2120):R399C ETV6(2120):c.1153-5_1153_1delAACAG ETV6(2120):p. L349P ETV6(2120):p. N385fs

      Genes: ETV6(2120) IKZF1(10320)

      Variants: 11905459G>A 12022436 G>A R181H V37M rs150089916 415 T>C L349P c. T1046C proline for leucine at codon 349 N385fs P214L R369Q R399C c.1153-5_1153_1delAACAG p. L349P p. N385fs

    2. Fusions involving ETV6 in leukemia have long been recognized. Other mutation types, including single nucleotide variations, insertions, deletions, frame-shifts and non-sense alterations are also becoming increasingly evi

      [Paragraph-level] PMCID: PMC4477877 Section: RESULTS PassageIndex: 12

      Evidence Type(s): Diagnostic, Functional

      Justification: Diagnostic: The passage discusses the identification of rare germline variants (V37M, R181H) in patients with B-ALL, indicating their association with the disease. Functional: Luciferase assays performed on the variants showed no significant changes in transcriptional repression activity compared to WT ETV6, indicating an assessment of their molecular function.

      Gene→Variant (gene-first): 2120:11905459G>A 2120:12022436 G>A 2120:R181H 2120:V37M 2120:rs150089916

      Genes: 2120

      Variants: 11905459G>A 12022436 G>A R181H V37M rs150089916

    3. To examine whether the L349P and N385fs mutations negatively impact translation or alter subcellular localization of the ETV6 protein, we performed cell fractionation assays and western blotting of HeLa cells transiently

      [Paragraph-level] PMCID: PMC4477877 Section: RESULTS PassageIndex: 10

      Evidence Type(s): Functional

      Justification: Functional: The detection of different localization patterns for the mutants P214L, R369Q, and R399C also suggests alterations in their molecular or biochemical function.

      Gene→Variant (gene-first): 2120:L349P 2120:N385fs 2120:P214L 2120:R369Q 2120:R399C

      Genes: 2120

      Variants: L349P N385fs P214L R369Q R399C

    4. To evaluate the functional consequences of these mutations, we first assessed whether L349P and N385fs might impair transcriptional repression by ETV6. HeLa cells were transiently co-transfected with constructs encoding

      [Paragraph-level] PMCID: PMC4477877 Section: RESULTS PassageIndex: 9

      Evidence Type(s): Functional

      Justification: Functional: The passage discusses how the mutations L349P, N385fs, P214L, R369Q, and R399C impair the transcriptional repression function of ETV6, indicating that these variants alter molecular function.

      Gene→Variant (gene-first): 2120:L349P 2120:N385fs 2120:P214L 2120:R369Q 2120:R399C

      Genes: 2120

      Variants: L349P N385fs P214L R369Q R399C

    5. Both ETV6 variants were absent in the National Heart Lung Blood Institute (NHLBI) Exome Sequencing Project (ESP) (http://evs.gs.washington.edu/EVS/), Exome Aggregation Consortium (ExAC) (http://exac.broadinstitute.org/),

      [Paragraph-level] PMCID: PMC4477877 Section: RESULTS PassageIndex: 7

      Evidence Type(s): Functional

      Justification: Functional: The passage discusses how the L349P and N385fs mutations are predicted to alter the molecular function of the ETV6 protein, including conformational changes and truncation that affect DNA interaction.

      Gene→Variant (gene-first): 2120:L349P 2120:N385fs

      Genes: 2120

      Variants: L349P N385fs

    6. Fibroblast and lymphocyte DNA from the proband with ALL and parents in Kindred 2 were analyzed by clinical whole exome sequencing (Ambry Genetics, Aliso Viejo, CA, USA). The proband and his mother harbored a heterozygous

      [Paragraph-level] PMCID: PMC4477877 Section: RESULTS PassageIndex: 6

      Evidence Type(s): Diagnostic, Oncogenic

      Justification: Diagnostic: The passage discusses the identification of a heterozygous deletion in ETV6 that is associated with the diagnosis of acute lymphoblastic leukemia (ALL) in the proband, indicating its role in defining the disease. Oncogenic: The variant N385fs is described as leading to a truncation of the ETV6 protein, which is implicated in tumor development, specifically in the context of acute lymphoblastic leukemia (ALL).

      Gene→Variant (gene-first): 2120:N385fs 2120:c.1153-5_1153_1delAACAG

      Genes: 2120

      Variants: N385fs c.1153-5_1153_1delAACAG

    7. DNA from 16 individuals in Kindred 1 (9 individuals with thrombocytopenia and/or ALL and 7 unaffected individuals) was subjected to Sanger sequencing for all exons of a targeted panel of leukemia-associated genes (Method

      [Paragraph-level] PMCID: PMC4477877 Section: RESULTS PassageIndex: 5

      Evidence Type(s): Diagnostic, Predisposing, Oncogenic

      Justification: Diagnostic: The variant 415 T>C is associated with thrombocytopenia and leukemia, as it was identified in all affected family members and absent in unaffected individuals, indicating its role in defining the disease. Predisposing: The passage describes the variant as being present in affected individuals and absent in unaffected individuals, suggesting it confers inherited risk for developing the disease, although it does not explicitly state that it is germline. Oncogenic: The variant is described in the context of leukemia, indicating its potential role in tumor development or progression, particularly as it is a missense mutation in a gene associated with leukemia.

      Gene→Variant (gene-first): 10320:415 T>C 2120:L349P 2120:c. T1046C 2120:proline for leucine at codon 349

      Genes: 10320 2120

      Variants: 415 T>C L349P c. T1046C proline for leucine at codon 349

    8. Inherited mutations of transcription factors have recently been associated with susceptibility to acute leukemia. Here we report two unrelated kindreds with inherited mutations in ETV6, the gene encoding the transcriptio

      [Paragraph-level] PMCID: PMC4477877 Section: ABSTRACT PassageIndex: 3

      Evidence Type(s): Predisposing, Functional

      Justification: Predisposing: The passage discusses inherited mutations in ETV6 that confer susceptibility to acute leukemia, indicating a germline origin and inherited risk for developing the disease. Functional: The passage describes how the ETV6 mutations (L349P and N385fs) alter the protein's localization and its ability to regulate gene expression, demonstrating a change in molecular function.

      Gene→Variant (gene-first): 2120:L349P 2120:N385fs

      Genes: 2120

      Variants: L349P N385fs

    9. Somatic mutations affecting ETV6 often occur in acute lymphoblastic leukemia (ALL), the most common childhood malignancy. The genetic factors that predispose to ALL remain poorly understood. Here we identify a novel germ

      [Paragraph-level] PMCID: PMC4477877 Section: ABSTRACT PassageIndex: 1

      Evidence Type(s): Predisposing, Oncogenic, Functional

      Justification: Predisposing: The passage describes a germline ETV6 p. L349P mutation identified in a kindred affected by thrombocytopenia and ALL, indicating an inherited risk for developing the disease. Oncogenic: The ETV6 p. N385fs mutation was found in leukemic cells and is associated with the deletion of wild type ETV6, suggesting its contribution to tumor development in the context of leukemia. Functional: The enforced expression of the ETV6 mutants showed impaired nuclear localization and a significantly reduced ability to regulate the transcription of ETV6 target genes, indicating an alteration in molecular function.

      Gene→Variant (gene-first): 2120:p. L349P 2120:p. N385fs

      Genes: 2120

      Variants: p. L349P p. N385fs

    10. Fusions involving ETV6 in leukemia have long been recognized. Other mutation types, including single nucleotide variations, insertions, deletions, frame-shifts and non-sense alterations are also becoming increasingly evi

      [Paragraph-level] PMCID: PMC4477877 Section: RESULTS PassageIndex: 12

      Evidence Type(s): Diagnostic, Functional

      Justification: Diagnostic: The passage discusses the identification of rare germline variants (V37M, R181H) in patients with B-ALL, indicating their association with the disease. Functional: Luciferase assays performed on the variants showed no significant changes in transcriptional repression activity compared to WT ETV6, indicating an assessment of their molecular function.

      Gene→Variant (gene-first): 2120:11905459G>A 2120:12022436 G>A 2120:R181H 2120:V37M 2120:rs150089916

      Genes: 2120

      Variants: 11905459G>A 12022436 G>A R181H V37M rs150089916

    11. To examine whether the L349P and N385fs mutations negatively impact translation or alter subcellular localization of the ETV6 protein, we performed cell fractionation assays and western blotting of HeLa cells transiently

      [Paragraph-level] PMCID: PMC4477877 Section: RESULTS PassageIndex: 10

      Evidence Type(s): Functional

      Justification: Functional: The detection of different localization patterns for the mutants P214L, R369Q, and R399C also suggests alterations in their molecular or biochemical function.

      Gene→Variant (gene-first): 2120:L349P 2120:N385fs 2120:P214L 2120:R369Q 2120:R399C

      Genes: 2120

      Variants: L349P N385fs P214L R369Q R399C

    12. To evaluate the functional consequences of these mutations, we first assessed whether L349P and N385fs might impair transcriptional repression by ETV6. HeLa cells were transiently co-transfected with constructs encoding

      [Paragraph-level] PMCID: PMC4477877 Section: RESULTS PassageIndex: 9

      Evidence Type(s): Functional

      Justification: Functional: The passage discusses how the mutations L349P, N385fs, P214L, R369Q, and R399C impair the transcriptional repression function of ETV6, indicating that these variants alter molecular function.

      Gene→Variant (gene-first): 2120:L349P 2120:N385fs 2120:P214L 2120:R369Q 2120:R399C

      Genes: 2120

      Variants: L349P N385fs P214L R369Q R399C

    13. Both ETV6 variants were absent in the National Heart Lung Blood Institute (NHLBI) Exome Sequencing Project (ESP) (http://evs.gs.washington.edu/EVS/), Exome Aggregation Consortium (ExAC) (http://exac.broadinstitute.org/),

      [Paragraph-level] PMCID: PMC4477877 Section: RESULTS PassageIndex: 7

      Evidence Type(s): Functional

      Justification: Functional: The passage discusses how the L349P and N385fs mutations are predicted to alter the molecular function of the ETV6 protein, including conformational changes and truncation that affect DNA interaction.

      Gene→Variant (gene-first): 2120:L349P 2120:N385fs

      Genes: 2120

      Variants: L349P N385fs

    14. Fibroblast and lymphocyte DNA from the proband with ALL and parents in Kindred 2 were analyzed by clinical whole exome sequencing (Ambry Genetics, Aliso Viejo, CA, USA). The proband and his mother harbored a heterozygous

      [Paragraph-level] PMCID: PMC4477877 Section: RESULTS PassageIndex: 6

      Evidence Type(s): Diagnostic, Oncogenic

      Justification: Diagnostic: The passage discusses the identification of a heterozygous deletion in ETV6 that is associated with the diagnosis of acute lymphoblastic leukemia (ALL) in the proband, indicating its role in defining the disease. Oncogenic: The variant N385fs is described as leading to a truncation of the ETV6 protein, which is implicated in tumor development, specifically in the context of acute lymphoblastic leukemia (ALL).

      Gene→Variant (gene-first): 2120:N385fs 2120:c.1153-5_1153_1delAACAG

      Genes: 2120

      Variants: N385fs c.1153-5_1153_1delAACAG

    15. DNA from 16 individuals in Kindred 1 (9 individuals with thrombocytopenia and/or ALL and 7 unaffected individuals) was subjected to Sanger sequencing for all exons of a targeted panel of leukemia-associated genes (Method

      [Paragraph-level] PMCID: PMC4477877 Section: RESULTS PassageIndex: 5

      Evidence Type(s): Diagnostic, Predisposing, Oncogenic

      Justification: Diagnostic: The variant 415 T>C is associated with thrombocytopenia and leukemia, as it was identified in all affected family members and absent in unaffected individuals, indicating its role in defining the disease. Predisposing: The passage describes the variant as being present in affected individuals and absent in unaffected individuals, suggesting it confers inherited risk for developing the disease, although it does not explicitly state that it is germline. Oncogenic: The variant is described in the context of leukemia, indicating its potential role in tumor development or progression, particularly as it is a missense mutation in a gene associated with leukemia.

      Gene→Variant (gene-first): 10320:415 T>C 2120:L349P 2120:c. T1046C 2120:proline for leucine at codon 349

      Genes: 10320 2120

      Variants: 415 T>C L349P c. T1046C proline for leucine at codon 349

    16. Inherited mutations of transcription factors have recently been associated with susceptibility to acute leukemia. Here we report two unrelated kindreds with inherited mutations in ETV6, the gene encoding the transcriptio

      [Paragraph-level] PMCID: PMC4477877 Section: ABSTRACT PassageIndex: 3

      Evidence Type(s): Predisposing, Functional

      Justification: Predisposing: The passage discusses inherited mutations in ETV6 that confer susceptibility to acute leukemia, indicating a germline origin and inherited risk for developing the disease. Functional: The passage describes how the ETV6 mutations (L349P and N385fs) alter the protein's localization and its ability to regulate gene expression, demonstrating a change in molecular function.

      Gene→Variant (gene-first): 2120:L349P 2120:N385fs

      Genes: 2120

      Variants: L349P N385fs

    17. Somatic mutations affecting ETV6 often occur in acute lymphoblastic leukemia (ALL), the most common childhood malignancy. The genetic factors that predispose to ALL remain poorly understood. Here we identify a novel germ

      [Paragraph-level] PMCID: PMC4477877 Section: ABSTRACT PassageIndex: 1

      Evidence Type(s): Predisposing, Oncogenic, Functional

      Justification: Predisposing: The passage describes a germline ETV6 p. L349P mutation identified in a kindred affected by thrombocytopenia and ALL, indicating an inherited risk for developing the disease. Oncogenic: The ETV6 p. N385fs mutation was found in leukemic cells and is associated with the deletion of wild type ETV6, suggesting its contribution to tumor development in the context of leukemia. Functional: The enforced expression of the ETV6 mutants showed impaired nuclear localization and a significantly reduced ability to regulate the transcription of ETV6 target genes, indicating an alteration in molecular function.

      Gene→Variant (gene-first): 2120:p. L349P 2120:p. N385fs

      Genes: 2120

      Variants: p. L349P p. N385fs